Optometry | Jotup

Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements

Retrieved on:

Thursday, August 10, 2023

Rosacea, Ophthalmology, TARS, Doctor of Philosophy, Optometry, Science, DB, Eyelid, MD, Patient, MITES, FDA, Disease, Pharmaceutical industry

IRVINE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced financial results for the second quarter ended June 30, 2023, and recent business achievements.

Key Points:

Completed enrollment of Galatea, a Phase 2a trial evaluating TP-04 for Rosacea, with topline data expected in 1H 2024
IRVINE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced financial results for the second quarter ended June 30, 2023, and recent business achievements.
“The FDA approval of XDEMVY for the treatment of Demodex blepharitis is a seminal milestone for Tarsus, the eye care community and most importantly for patients, many of whom have struggled for years without an approved, effective treatment option,” said Bobak Azamian, MD, PhD, Chief Executive Officer and Chairman of Tarsus.
“We are well-positioned and well-funded, expect to launch XDEMVY later this month to capture the potentially very significant patient demand, and anticipate rapid adoption among eye care providers and meaningful prescription volume in the early days following XDEMVY’s entrance into the market.”
First and only approved therapeutic for DB, a highly prevalent eyelid disease that impacts approximately 25 million eye care patients in the U.S.
XDEMVY targets the root cause of DB and in pivotal trials demonstrated significant improvement in eyelids (reduction of collarettes, the pathognomonic sign of the disease, to no more than 2 collarettes per upper lid), mite eradication (mite density of 0 mites per lash) and erythema cure (Grade 0)
Completed recruitment of our 85-person sales force targeting ~15K optometrists and ophthalmologists, which represents >80% of the projected market; expect sales force to be deployed by the end of August when we anticipate product to be available
“Look at the Lids” disease education campaign has generated nearly 300K unique website visits, up from 200K last quarter and nearly 3M digital/media impressions, an increase of 700K impressions since last quarter

Eyenovia Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on:

Thursday, August 10, 2023

NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray) for mydriasis and developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced its financial and operating results for the second quarter ended June 30, 2023.

Key Points:

Advanced its pre-NDA presbyopia program, Apersure (Microline), and anticipates commencing the manufacture of registration batches in the fourth quarter of 2023.
Research and development expenses totaled approximately $2.8 million for the second quarter of 2023 as compared to $3.6 million for the second quarter of 2022.
For the second quarter of 2023, general and administrative expenses were approximately $3.1 million, compared to $3.5 million for the second quarter of 2022.
Total operating expenses for the second quarter of 2023 were approximately $6.0 million compared to $7.1 million for the second quarter of 2022.

"Optical tomero…spetogra-what?" Specsavers shares the importance of Optical Coherence Tomography (OCT) with a new multi-channel campaign

Retrieved on:

Thursday, August 10, 2023

"The goal of this campaign is to raise awareness of the importance of asking for OCT at every eye exam," said Bill Moir, Managing Director, Specsavers Canada.

Key Points:

"The goal of this campaign is to raise awareness of the importance of asking for OCT at every eye exam," said Bill Moir, Managing Director, Specsavers Canada.
"Making this technology accessible through every standard eye exam is the foundation of Specsavers journey to help end preventable blindness."
OCT also supports identifications of other underlying health conditions such as hypertension, diabetes and even life-threatening conditions such as tumours.
The centrepiece of the campaign is a TV ad that sees Canadians stumbling on their words when pronouncing "Optical Coherence Tomography."

Virginia's Largest Ophthalmology, Optometry Clinic, and Storefront Transitions to eClinicalWorks Vision Solutions

Retrieved on:

Thursday, August 10, 2023

eClinicalWorks® , the largest ambulatory cloud EHR, today announced Virginia Eye Institute’s (VEI) successful transition to eClinicalWorks and healow solutions.

Key Points:

eClinicalWorks® , the largest ambulatory cloud EHR, today announced Virginia Eye Institute’s (VEI) successful transition to eClinicalWorks and healow solutions.
With eClinicalWorks Vision Solutions, VEI can better manage prescriptions, track inventory, and use specialized modules within the eClinicalWorks EHR.
“We saw how eClinicalWorks shares this value and offers the best software solutions for ophthalmology and optometry.
“We’ve thoroughly enjoyed working together to further enhance our existing vision solutions, which are revolutionizing operations for vision centers across the nation.

Warby Parker Announces Second Quarter 2023 Results

Retrieved on:

Wednesday, August 9, 2023

Warby Parker Inc. (NYSE: WRBY) (“Warby Parker” or the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the second quarter ended June 30, 2023.

Key Points:

Warby Parker Inc. (NYSE: WRBY) (“Warby Parker” or the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the second quarter ended June 30, 2023.
Warby Parker ended the second quarter of 2023 with $212.7 million in cash and cash equivalents.
“Given our better than anticipated results in the first half of 2023, we are raising our full year guidance.
A conference call to discuss Warby Parker’s second quarter 2023 results, as well as third quarter and full year 2023 outlook, is scheduled for 8:00 a.m.

Survey Reveals 1 In 6 Quebec Parents Have Yet to Take Their Child to the Eye Doctor

Retrieved on:

Tuesday, August 8, 2023

Learning, EssilorLuxottica, Face, Parent, Patrice Stellest, Paratriathlon, Research, Optometry, Risk, Child, School, Near-sightedness, Achievement Medal, News, Toy, Birth control, Tutoring, Telescopic sight

The survey, which sampled responses from 1,019 Canadian parents, reveals that 1 in 6 Quebec parents have never brought their children to the eye doctor, while most Quebec parents (81.1%) have brought their child to the dentist within the past year.

Key Points:

The survey, which sampled responses from 1,019 Canadian parents, reveals that 1 in 6 Quebec parents have never brought their children to the eye doctor, while most Quebec parents (81.1%) have brought their child to the dentist within the past year.
Essilor® knows how much time and thought parents put into raising healthy and happy children and its goal is to remind parents just how important eye health is to a child’s development.
While it is possible to help prevent myopia onset and myopia progression, the condition is irreversible once the eyeball has elongated and myopia has developed.
Many parents across Quebec may benefit from learning more about how preventive eye care can help maintain their children's academic success,” explains Dr. Langis Michaud.

STAY COOL WHILE PREPARING FOR BACK TO SCHOOL

Retrieved on:

Thursday, August 3, 2023

Pizzazz, Taste, Seasoning, Food, Snack, SPICE, Parent, EYE, HOW, Vegetable, Optometry, School, Achievement Medal, Child, Lunch, Near-sightedness, TIME, Toy

NEW YORK, Aug. 3, 2023 /PRNewswire/ -- It's hard to believe but back-to-school season is already upon us and now is the perfect time to equip your kids with everything they need to take on the new school year.

Key Points:

She also provides tips on preparing fun lunch and snack ideas, time saving hacks, how to stay organized, and more!
SPICE UP LUNCHTIME: The tedious task of making kids' school lunches gets old fast, so turn traditional lunch box treats into a fun and tasty experience.
Spice things up to keep it interesting, add some pizzazz to the presentation, or prep the food in a different way.
With the right treatment, children can have improved focus and perform better in school and in extracurricular activities as their vision improves.

Eyenovia Announces First Commercial Sale of Mydcombi™

Retrieved on:

Thursday, August 3, 2023

NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for mydriasis and developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced the first commercial sale of Mydcombi. Mydcombi was approved by the US Food and Drug Administration on May 8, 2023. The initial sale was to world-renowned board-certified ophthalmologist Dr. Nathan M. Radcliffe, who has become the first physician in the U.S. to incorporate Mydcombi into his daily practice.

Key Points:

Mydcombi was approved by the US Food and Drug Administration on May 8, 2023.
The initial sale was to world-renowned board-certified ophthalmologist Dr. Nathan M. Radcliffe, who has become the first physician in the U.S. to incorporate Mydcombi into his daily practice.
The product should not be used in patients with known hypersensitivity to any component of the formulation.
To report SUSPECTED ADVERSE REACTIONS, contact Eyenovia, Inc. At 1-833-393-6684 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch)

Federman & Sherwood Investigates Family Vision of Anderson, P.A. for Data Breach

Retrieved on:

Wednesday, August 2, 2023

Legal, Networks, Optical, Health, Data Management, Professional Services, Technology, Class Action Lawsuit, Allergy, Optometry, Name, Address, Social, Federman, Sherwood, Family, Social Security, Retail

The law firm of Federman & Sherwood has initiated an investigation into Family Vision of Anderson with respect to their recent data breach.

Key Points:

The law firm of Federman & Sherwood has initiated an investigation into Family Vision of Anderson with respect to their recent data breach.
On July 26, 2023, Family Vision of Anderson notified 62,631 individuals that the company experienced a data breach after an unauthorized party accessed sensitive consumer data entrusted to the company.
According to Family Vision of Anderson, they determined that information stored on their servers may have been subject to unauthorized access from May 21, 2023 through May 22, 2023.
If you wish to discuss this action, obtain further information, and/or participate in this litigation, please contact Lacrista A. Bagley either by email at [email protected] or visit our firm’s website www.federmanlaw.com .

Orlando Health Welcomes Florida Medical Clinic

Retrieved on:

Tuesday, August 1, 2023

ORLANDO, Fla., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Effective today, Orlando Health announces its expansion into Hillsborough and Pasco counties by joining forces with Florida Medical Clinic (FMC).

Key Points:

ORLANDO, Fla., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Effective today, Orlando Health announces its expansion into Hillsborough and Pasco counties by joining forces with Florida Medical Clinic (FMC).
“Florida Medical Clinic has provided its patients with access to distinguished physicians and providers for three decades,” said David Strong, president and CEO, Orlando Health.
Joining Orlando Health enables us to further advance our ability to provide innovative and quality care with greater capabilities and sustainability than ever before.”
Founded in 1993, Florida Medical Clinic is a multi-specialty medical group dedicated to improving both the quality and delivery of healthcare to the communities it serves.
Florida Medical Clinic offers two urgent care centers, as well as two surgery centers accredited by the Accreditation Association for Ambulatory Health Care (AAHC).